Premier Graphene (BIEI) 10-Q 15 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	11-May-15
Document And Entity Information
Entity Registrant Name	PREMIER BIOMEDICAL INC
Entity Central Index Key	1515740
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		21,757,175
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash	$95,930	$102,599
Prepaid Expenses	4,450	9,450
Loan origination costs	7,085	3,473
Total current assets	107,465	115,522
Property and equipment, net	4,702	5,109
Total assets	112,167	120,631
Current liabilities:
Accounts Payable	209,489	147,491
Accounts payable, related parties	26,924	25,299
Accrued interest	4,197	721
Convertible notes payable, net of discounts of $94,834 and $71,621 at March 31, 2015 and December 31, 2014, respectively	118,453	14,879
Total current liabilities	359,063	188,390
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.00001 par value, 300,000,000 shares authorized, 21,757,175 shares issued and outstanding at March 31, 2015 and December 31, 2014	218	218
Additional paid in capital	9,215,947	8,127,649
Accumulated deficit	-9,463,061	-8,195,626
Total stockholders' equity (deficit)	-246,896	-67,759
Total liabilities and stockholders' equity (deficit)	$112,167	$120,631

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current liabilities:
Convertible notes payable, net of discounts	$94,834	$71,621
Stockholders' equity (deficit):
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized shares	10,000,000	10,000,000
Preferred stock, issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock, par value	$0.00	$0.00
Common stock, authorized shares	300,000,000	300,000,000
Common stock, issued shares	21,757,175	21,757,175
Common stock, outstanding shares	21,757,175	21,757,175

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Condensed Statements Of Operations
Revenue
Operating expenses:
Research and development	116,802	2,742
General and administrative	23,300	47,817
Professional fees	1,086,332	227,292
Total operating expenses	1,226,434	277,851
Net operating loss	-1,226,434	-277,851
Other expense:
Interest expense	-41,001	-29,455
Total other expenses	-41,001	-29,455
Net loss	($1,267,435)	($307,306)
Weighted average number of common shares outstanding - basic and fully diluted	21,757,175	18,971,625
Net loss per share - basic and fully diluted	($0.06)	($0.02)

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss)	($1,267,435)	($307,306)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	407	233
Amortization of loan origination costs	2,138
Imputed interest on non-interest bearing related party debts		134
Amortization of debt discount	35,387
Stock based compensation, related parties	825,778
Stock based compensation	209,957	146,751
Decrease (increase) in assets:
Prepaid expenses	5,000	470
Increase (decrease) in liabilities:
Accounts payable	61,998	-104,578
Accounts payable, related parties	1,625	-36,865
Accrued interest	3,476	-3,298
Net cash used in operating activities	-121,669	-304,459
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from convertible notes payable	115,000
Repayments on notes payable, related parties		-109,000
Proceeds from the sale of common stock		511,250
Net cash provided by financing activities	115,000	402,250
NET CHANGE IN CASH	-6,669	97,791
CASH AT BEGINNING OF PERIOD	102,599	15,800
CASH AT END OF PERIOD	95,930	113,591
SUPPLEMENTAL INFORMATION:
Interest paid		32,619
Income taxes paid
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Discount on beneficial conversion feature on convertible note	$52,563

Nature_of_Business_and_Signifi

Nature of Business and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Note 1 - Nature of Business and Significant Accounting Policies	Nature of Business
	Premier Biomedical, Inc. (“the Company”) was incorporated in the State of Nevada on May 10, 2010 (“Inception”). The Company was formed to develop and market medications and procedures that address a significant number of the most highly visible health issues currently affecting mankind. The Company will market these medications and procedures to leading worldwide pharmaceutical firms via publication in medical journals and by direct contact.
	Basis of Presentation
	The accompanying unaudited, condensed financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, these statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. It is suggested that these statements be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.
	JOBS Act
	We are an “emerging growth company” as defined in the recently-enacted JOBS Act, and we are eligible to take advantage of certain exemptions from various reporting and disclosure requirements that are applicable to public companies that are not “emerging growth companies.” As an “emerging growth company” under the JOBS Act, we are permitted to, and intend to, rely on exemptions from certain reporting and disclosure requirements, which may make our future public filings different than that of other public companies.
	Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain new accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(2) of the JOBS Act, that allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.
	We will remain an “emerging growth company” until the earliest of: (i) the last day of the fiscal year during which we had total annual gross revenues of $1 billion or more, (ii) the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement, (iii) the date on which we have, during the previous 3-year period, issued more than $1 billion in non-convertible debt or (iv) the date on which we are deemed a “large accelerated filer” as defined under the federal securities laws.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	The Company maintains cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents.
	Patent Rights and Applications
	Patent rights and applications costs include the acquisition costs and costs incurred for the filing of patents. Patent rights and applications are amortized on a straight-line basis over the legal life of the patent rights beginning at the time the patents are approved. Patent costs for unsuccessful patent applications are expensed when the application is terminated.
	Fair Value of Financial Instruments
	Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments.
	Basic and Diluted Loss Per Share
	The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.
	Stock-Based Compensation
	Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company’s stock based compensation consisted of the following during the three months ended March 31, 2015 and 2014, respectively:
		March 31,		March 31,
		2015		2014
	Common stock issued for services	$	-	$	97,000
	Warrants issued for services		209,957		49,751
	Warrants issued for services, related parties		825,778		-
	Total stock based compensation	$	1,035,735	$	146,751
	Revenue Recognition
	Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales have not yet commenced.
	Advertising and Promotion
	All costs associated with advertising and promoting products are expensed as incurred. These expenses were $11,517 and $35,317 for the three months ended March 31, 2015 and 2014, respectively.
	Income Taxes
	Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.
	Uncertain Tax Positions
	In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.
	Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities.
	The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.
	Recent Accounting Pronouncements
	In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, Interest–Imputation of Interest (Subtopic 835-30) (“ASU 2015-03”), which changes the presentation of debt issuance costs in financial statements. ASU 2015-03 requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. It is effective for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The new guidance will be applied retrospectively to each prior period presented. The Company is currently in the process of evaluating the impact of adoption of ASU 2015-03 on its balance sheets.
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period, and early application is not permitted. ASU 2014-09 allows for either full retrospective or modified retrospective adoption. We do not expect the adoption of the new provisions to have a material impact on our financial condition or results of operations.
	No other new accounting pronouncements, issued or effective during the first quarter of 2015, have had or are expected to have a significant impact on the Company’s financial statements.

Going_Concern

Going Concern	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Note 2 - Going Concern	As shown in the accompanying financial statements, the Company has no revenues, incurred net losses from operations resulting in an accumulated deficit of $9,463,061, and had negative working capital of ($251,598) at March 31, 2015. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company is currently seeking additional sources of capital to fund short term operations. The Company, however, is dependent upon its ability to secure equity and/or debt financing and there are no assurances that the Company will be successful; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern.
	The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. The financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Related_Parties

Related Parties	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Note 3 - Related Parties	Accounts Payable
	The Company owed $12,729 and $11,069 as of March 31, 2015 and December 31, 2014, respectively, to entities owned by the Chairman of the Board of Directors. The amounts are related to patent costs paid by the Chairman on behalf of the Company.
	The Company owed $431 and $465 as of March 31, 2015 and December 31, 2014, respectively, to the Company’s CEO for reimbursable expenses.
	The Company owed $13,765 and $13,765 as of March 31, 2015 and December 31, 2014, respectively, to one of the Company’s Board of Directors for reimbursable expenses.
	Warrants
	A total of $825,778 and $-0- of previously issued warrants were amortized and expensed to professional fees as stock-based compensation during the three months ending March 31, 2015 and 2014, respectively.

Patent_Rights_and_Applications

Patent Rights and Applications	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Note 4 - Patent Rights and Applications	The Company amortizes its patent rights and applications on a straight line basis over the expected useful technological or economic life of the patents, which is typically 17 years from the legal approval of the patent applications. As of January 1, 2013, the Company has elected to expense all of their patent rights and application costs due to difficulties associated with having to prove the value of their future economic benefits. All patent applications are currently pending and the Company has no patents that have yet been approved. It is the Company’s policy that it performs reviews of the carrying value of its patent rights and applications on an annual basis.
	On March 4, 2015, we entered into a Patent License Agreement (“PLA”) with the University of Texas at El Paso (“UTEP”) regarding our joint research and development of CTLA-4 Blockade with Metronomic Chemotherapy for the Treatment of Breast Cancer. This is the first PLA with UTEP following our Collaborative Agreement with them dated May 9, 2012, and memorializes the joint ownership of the applicable patent and the financial and other terms related thereto.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Note 5 - Fair Value of Financial Instruments	Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value.
	The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows:
	Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
	Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
	Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability.
	The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of March 31, 2015 and December 31, 2014, respectively:
		Fair Value Measurements at
		31-Mar-15
		Level 1		Level 2			Level 3
	Assets
	Cash	$	95,930	$	-		$	-
	Total assets		95,930		-			-
	Liabilities
	Convertible note payable, net of discounts		-		118,453			-
	Total liabilities		-		118,453			-
		$	95,930	$	(118,453	)	$	-
		Fair Value Measurements at
		31-Dec-14
		Level 1		Level 2			Level 3
	Assets
	Cash	$	102,599	$	-		$	-
	Total assets		102,599		-			-
	Liabilities
	Convertible note payable, net of discounts		-		14,879			-
	Total liabilities		-		14,879			-
		$	102,599	$	(14,879	)	$	-
	The fair values of our related party debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35.
	There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the three months ended March 31, 2015 or the year ended December 31, 2014.

Convertible_Note_Payable

Convertible Note Payable	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Note 6 - Convertible Note Payable	Convertible notes payable consist of the following at March 31, 2015 and December 31, 2014, respectively:
		31-Mar-15		31-Dec-14
	On February 24, 2015, we entered into a Securities Purchase Agreement with Adar Bays, LLC (“Adar Bays”), pursuant to which we sold to Adar Bays an 8% Convertible Promissory Note in the original principal amount of $44,100.00 (the “First Adar Note”). The Note has a maturity date of February 24, 2016, and is convertible after 180 days into our common stock at the higher of (i) $0.001 cents per share or (ii) 70% of the average of the two (2) lowest closing prices of our common stock for the fifteen (15) trading days prior to receipt of a conversion notice from Adar Bays. The shares of common stock issuable upon conversion of the Note will be restricted securities as defined in Rule 144 promulgated under the Securities Act of 1933. The Note can be prepaid by us at a premium as follows:	$	44,100	$	-
	(a) between 1 and 30 days after issuance – 115% of the principal amount;
	(b) between 31 and 60 days after issuance – 121% of the principal amount;
	(c) between 61 and 90 days after issuance – 127% of the principal amount;
	(d) between 91 and 120 days after issuance – 133% of the principal amount;
	(e) between 121 and 150 days after issuance – 139% of the principal amount; and
	(f) between 151 and 180 days after issuance – 140% of the principal amount.
	There is no right to pre-payment after 180 days. The purchase and sale of the Note closed on March 2, 2015, the date that the purchase price was delivered to us.
	On January 30, 2015, we entered into a Securities Purchase Agreement with LG Capital Funding, LLC (“LG Capital”), pursuant to which we sold to LG Capital a 8% Convertible Promissory Note in the original principal amount of $82,687.00 (the “ Second LG Note”). The Note has a maturity date of January 29, 2016, and is convertible after 180 days into our common stock at the higher of (i) $0.001 cents per share or (ii) 70% of the average of the two (2) lowest closing bid prices of our common stock for the fifteen (15) trading days prior to receipt of a conversion notice from LG Capital. The shares of common stock issuable upon conversion of the Note will be restricted securities as defined in Rule 144 promulgated under the Securities Act of 1933. The Note can be prepaid by us at a premium as follows:		82,687		-
	(a) between 1 and 30 days after issuance – 115% of the principal amount;
	(b) between 31 and 60 days after issuance – 121% of the principal amount;
	(c) between 61 and 90 days after issuance – 126% of the principal amount;
	(d) between 91 and 120 days after issuance – 132% of the principal amount;
	(e) between 121 and 150 days after issuance – 138% of the principal amount; and
	(f) between 151 and 180 days after issuance – 140% of the principal amount.
	There is no right to pre-payment after 180 days. The purchase and sale of the Note closed on January 30, 2015, the date that the purchase price was delivered to us.
	On November 25, 2014, the Company received an unsecured loan from Typenex Co-Investment, LLC (“First Typenex Note”) in the amount of $86,500, bearing interest at 10%, maturing on August 25, 2015, in exchange for net proceeds of $75,000 after the deduction of $4,000 of loan origination costs and an original issue discount (“OID”) of $7,500. The Company also issued Typenex warrants to purchase 351,455 shares of common stock at a strike price of $0.18 per share over a five year term from the date of investment. The principal and interest is convertible into shares of common stock at the discretion of the note holder at the lesser of (i) $0.18 per share, or (ii) 70% (the “Conversion Factor”) multiplied by the Market Price (as defined in the Note). If the Market Price of our common stock falls below $0.10 per share after the issuance of the Note, the Conversion Factor will automatically be reduced by 5% for all conversions completed while the Market Price is below $0.10 per share. Notwithstanding the foregoing, so long as no Event of Default has occurred, the Conversion Price shall be not less than $0.0001 (the “Conversion Floor”). For the avoidance of doubt, upon the occurrence of an Event of Default, the Conversion Floor shall not apply to any future Conversions and shall be of no further force or effect. The note can be prepaid upon notice to Typenex any time prior to the first conversion at a premium of 120% of the then outstanding balance of the Note. The note carries a default interest rate of 22% per annum.		86,500		86,500
	Total convertible notes payable		213,287		86,500
	Less unamortized debt discounts:
	Discount on beneficial conversion feature		65,166		32,137
	Original issue discount		9,216		6,511
	Discount on warrants		20,452		32,973
	Convertible notes payable		118,453		14,879
	Less: current portion		118,453		14,879
	Convertible notes payable, less current portion	$	-	$	-
	The Company recognized interest expense for the three months ended March 31, 2015 and 2014, respectively, as follows:
		March 31,		March 31,
		2015		2014
	Interest on convertible notes	$	3,476	$	-
	Interest on related party loans		-		29,455
	Amortization of loan origination costs		2,138		-
	Amortization of beneficial conversion feature		19,534		-
	Amortization of OID		3,332		-
	Amortization of warrants		12,521		-
	Total interest expense	$	41,001	$	29,455
	In addition, the Company recognized and measured the embedded beneficial conversion feature present in the convertible debts by allocating a portion of the proceeds equal to the intrinsic value of the feature to additional paid-in-capital. The intrinsic value of the feature was calculated on the commitment date using the effective conversion price of the convertible debt. This intrinsic value is limited to the portion of the proceeds allocated to the convertible debt.
	The aforementioned accounting treatment resulted in debt discounts equal to $52,563 and $37,019 during the three months ended March 31, 2015 and the year ended December 31, 2014, respectively. The discount is amortized on a straight line basis from the dates of issuance until the earlier of the stated redemption date of the debts, as noted above or the actual settlement date. During the three months ended March 31, 2015 and 2014, the Company recorded debt amortization expense in the amount of $19,534 and $-0-, respectively, attributed to the aforementioned debt discounts.
	The convertible notes, consisting of total original face values of $44,100 from Adar Bays, LLC, $82,687 from LG Capital Funding, LLC, and $86,500 from Typenex Co-Investment, LLC that created the beneficial conversion features carried a default provision that placed a “maximum share amount” on the note holder that can be owned as a result of the conversions to common stock by the note holder of 4.99% of the issued and outstanding shares of the Company.
	Adar Bays, LLC Convertible Note
	On February 24, 2015, we entered into a Securities Purchase Agreement with Adar Bays, LLC, pursuant to which we sold to Adar Bays an 8% Convertible Promissory Note (“First Adar Bays Note”) in the original principal amount of $44,100. The First Adar Bays Note has a maturity date of February 24, 2016, and is convertible after 180 days into our common stock at the higher of (i) $0.001 cents per share or (ii) 70% of the average of the two (2) lowest closing prices of our common stock for the fifteen (15) trading days prior to receipt of a conversion notice.
	The shares of common stock issuable upon conversion of the First Adar Bays Note are restricted securities as defined in Rule 144 promulgated under the Securities Act of 1933. The issuance of the First Adar Bays Note was exempt from the registration requirements of the Securities Act of 1933 pursuant to Rule 506 of Regulation D promulgated thereunder. The purchaser was an accredited and sophisticated investor, familiar with our operations, and there was no solicitation.
	The Company evaluated the First Adar Bays Note and determined that the shares issuable pursuant to the conversion option were determinate due to the Fixed Conversion Price and, as such, did not constitute a derivative liability. The beneficial conversion feature discount resulting from the conversion price of $0.0473 below the market price on February 24, 2015 of $0.14 provided a value of $20,420, of which $1,958 and $-0- was amortized during the three months ended March 31, 2015 and 2014, respectively.
	LG Capital Funding, LLC Convertible Note
	On January 30, 2015, we entered into a Securities Purchase Agreement with LG Capital Funding, LLC, pursuant to which we sold to LG Capital an 8% Convertible Promissory Note (“Second LG Capital Note”) in the original principal amount of $82,687. The Second LG Capital Note has a maturity date of January 29, 2016, and is convertible after 180 days into our common stock at the higher of (i) $0.001 cents per share or (ii) 70% of the average of the two (2) lowest closing prices of our common stock for the fifteen (15) trading days prior to receipt of a conversion notice.
	The shares of common stock issuable upon conversion of the Second LG Capital Note are restricted securities as defined in Rule 144 promulgated under the Securities Act of 1933. The issuance of the Second LG Capital Note was exempt from the registration requirements of the Securities Act of 1933 pursuant to Rule 506 of Regulation D promulgated thereunder. The purchaser was an accredited and sophisticated investor, familiar with our operations, and there was no solicitation.
	The Company evaluated the Second LG Capital Note and determined that the shares issuable pursuant to the conversion option were determinate due to the Fixed Conversion Price and, as such, did not constitute a derivative liability. The beneficial conversion feature discount resulting from the conversion price of $0.042 below the market price on January 30, 2015 of $0.14 provided a value of $32,143, of which $5,372- and $-0- was amortized during the three months ended March 31, 2015 and 2014, respectively.
	Typenex Co-Investment, LLC Convertible Note
	On November 25, 2014, we entered into a Securities Purchase Agreement with Typenex Co-Investment, LLC, pursuant to which we sold to Typenex a 10% Convertible Promissory Note (“First Typenex Note”) in the original principal amount of $86,500. The First Typenex Note has a maturity date of August 25, 2015, and is convertible into our common stock at the lesser of (i) $0.18 per share, or (ii) 70% (the “Conversion Factor”) multiplied by the Market Price (as defined in the Note). If the Market Price of our common stock falls below $0.10 per share after the issuance of the Note, the Conversion Factor will automatically be reduced by 5% for all conversions completed while the Market Price is below $0.10 per share. Notwithstanding the foregoing, so long as no Event of Default has occurred, the Conversion Price shall be not less than $0.0001 (the “Conversion Floor”). For the avoidance of doubt, upon the occurrence of an Event of Default, the Conversion Floor shall not apply to any future Conversions and shall be of no further force or effect.
	The shares of common stock issuable upon conversion of the First Typenex Note are restricted securities as defined in Rule 144 promulgated under the Securities Act of 1933. The issuance of the First Typenex Note is exempt from the registration requirements of the Securities Act of 1933 pursuant to Rule 506 of Regulation D promulgated thereunder. The purchaser was an accredited and sophisticated investor, familiar with our operations, and there was no solicitation.
	The Company evaluated the First Typenex Note and determined that the shares issuable pursuant to the conversion option were determinate due to the Fixed Conversion Price and, as such, does not constitute a derivative liability. The beneficial conversion feature discount resulting from the conversion price of $0.1019 below the market price on November 25, 2014 of $0.225 provided a value of $37,019, of which $12,204 and $-0- was amortized during the three months ended March 31, 2015 and 2014, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Note 7 - Commitments and Contingencies	On May 9, 2012, the Company entered into a Collaborative Agreement with the University of Texas at El Paso. Pursuant to the terms of the Agreement, the Company will work jointly with the University to develop a series of research and development programs around its sequential-dialysis technology in the areas of Alzheimer's Disease, Traumatic Brain Injury (TBI), Chronic Pain Syndrome, Fibromyalgia, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease), Blood Sepsis, Cancer, Heart Attacks and Strokes. The programs will utilize the facilities at one or more of the University of Texas’ campuses. The Company will pay the University’s actual overhead for the projects, plus a negotiated facility and administration overhead expense, and 10% of all gross revenues associated with the sale, license and/or royalties of all products and treatment procedures directly affiliated with programs. Intellectual property jointly invented and developed as a result of the projects will be owned jointly by the University and the Company. The agreement has an initial term of five (5) years, and is renewable upon mutual agreement of the parties.
	On March 4, 2015, we entered into a Patent License Agreement (PLA) with the University of Texas at El Paso (UTEP) regarding our joint research and development of CTLA-4 Blockade with Metronomic Chemotherapy for the Treatment of Breast Cancer. This is the first PLA with UTEP following our Collaborative Agreement with them dated May 9, 2012, and memorializes the joint ownership of the applicable patent and the financial and other terms related thereto.

Changes_in_Stockholders_Equity

Changes in Stockholders Equity (Deficit)	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Note 8 - Changes in Stockholders Equity (Deficit)	Convertible Preferred Stock, Series A
	The Company has 10,000,000 authorized shares of Preferred Stock, of which 2,000,000 shares of $0.001 par value Series A Convertible Preferred Stock (“Series A Preferred Stock”) have been designated. Each share of Series A Preferred Stock is convertible, at the option of the holder thereof, at any time after the issuance of such share into one (1) fully paid and non-assessable share of Common Stock. Each outstanding share of Series A Preferred Stock is entitled to one hundred (100) votes per share on all matters to which the shareholders of the Corporation are entitled or required to vote. The Company shall reserve and keep available out of its authorized but unissued shares of Common Stock such number of shares sufficient to effect the conversions. No shares of Series A Preferred Stock have been granted to date.
	No preferred shares were issued during the three months ended March 31, 2015.
	Common Stock
	The Company has 300,000,000 authorized shares of $0.00001 par value Common Stock.
	No common shares were issued during the three months ended March 31, 2015.
	Beneficial Conversion Feature
	On February 24, 2015, the Company entered into a convertible promissory note with Adar Bays, LLC. The beneficial conversion feature discount resulting from the conversion price that was $0.0473 below the market price of $0.14 on the February 24, 2015, origination date resulted in a debt discount value of $20,420 that was recognized as additional paid in capital and was amortized on a straight line basis over the life of the loan.
	On January 30, 2015, the Company entered into a convertible promissory note with LG Capital Funding, LLC. The beneficial conversion feature discount resulting from the conversion price that was $0.042 below the market price of $0.14 on the January 30, 2015, origination date resulted in a debt discount value of $32,143 that was recognized as additional paid in capital and was amortized on a straight line basis over the life of the loan.

Common_Stock_Warrants

Common Stock Warrants	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Note 9 - Common Stock Warrants	On March 20, 2015, the Company granted cashless common stock warrants to an independent contractor to purchase a total of 500,000 shares of common stock at $0.20 per share for investor relation services. The warrants are exercisable over five (5) years from March 20, 2015. The warrants vest in accordance with the schedule presented below, whereby the price per share is defined by the closing bid price over three consecutive trading days:
		·	125,000 warrants will vest at $0.20 per share
		·	125,000 warrants will vest at $0.30 per share
		·	125,000 warrants will vest at $0.40 per share
		·	125,000 warrants will vest at $0.50 per share
	The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 204% and a call option value of $0.1166, was $58,301. The vesting period is indeterminate, therefore, the Company recognized the entire $58,301 of stock based compensation expense during the three months ended March 31, 2015.
	A total of $1,035,735 and $49,751 of warrants were amortized and expensed to professional fees as stock-based compensation during the three months ending March 31, 2015 and 2014, respectively, including $825,778 during the three months ending March 31, 2015 related to warrants previously issued to related parties.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Note 10 - Income Taxes	The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences.
	For the three months ended March 31, 2015, and the year ended December 31, 2014, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At March 31, 2015, and December 31, 2014, the Company had approximately $2,157,014 and $1,930,314 of federal net operating losses, respectively. The net operating loss carry forwards, if not utilized, will begin to expire in 2031.
	The components of the Company’s deferred tax asset are as follows:
		March 31,			December 31,
		2015			2014
	Deferred tax assets:
	Net operating loss carry forwards	$	755,000		$	675,610
	Net deferred tax assets before valuation allowance	$	755,000		$	675,610
	Less: Valuation allowance		(755,000	)		(675,610	)
	Net deferred tax assets	$	-		$	-
	Based on the available objective evidence, including the Company’s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at March 31, 2015, and December 31, 2014, respectively.
	A reconciliation between the amounts of income tax benefit determined by applying the applicable U.S. and state statutory income tax rate to pre-tax loss is as follows:
		March 31,			December 31,
		2015			2014
	Federal and state statutory rate		35%			35%
	Change in valuation allowance on deferred tax assets		-35%			-35%
	In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Note 11 - Subsequent Events	There were no subsequent events to report through the date of this filing.

Nature_of_Business_and_Signifi1

Nature of Business and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Nature Of Business And Significant Accounting Policies Policies
Nature of Business	Premier Biomedical, Inc. (“the Company”) was incorporated in the State of Nevada on May 10, 2010 (“Inception”). The Company was formed to develop and market medications and procedures that address a significant number of the most highly visible health issues currently affecting mankind. The Company will market these medications and procedures to leading worldwide pharmaceutical firms via publication in medical journals and by direct contact.
Basis of Presentation	The accompanying unaudited, condensed financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, these statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. It is suggested that these statements be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.
JOBS Act	We are an “emerging growth company” as defined in the recently-enacted JOBS Act, and we are eligible to take advantage of certain exemptions from various reporting and disclosure requirements that are applicable to public companies that are not “emerging growth companies.” As an “emerging growth company” under the JOBS Act, we are permitted to, and intend to, rely on exemptions from certain reporting and disclosure requirements, which may make our future public filings different than that of other public companies.
	Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain new accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(2) of the JOBS Act, that allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.
	We will remain an “emerging growth company” until the earliest of: (i) the last day of the fiscal year during which we had total annual gross revenues of $1 billion or more, (ii) the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement, (iii) the date on which we have, during the previous 3-year period, issued more than $1 billion in non-convertible debt or (iv) the date on which we are deemed a “large accelerated filer” as defined under the federal securities laws.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	The Company maintains cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents.
Patent rights and applications	Patent rights and applications costs include the acquisition costs and costs incurred for the filing of patents. Patent rights and applications are amortized on a straight-line basis over the legal life of the patent rights beginning at the time the patents are approved. Patent costs for unsuccessful patent applications are expensed when the application is terminated.
Fair Value of Financial Instruments	Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments.
Basic and Diluted Loss Per Share	The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.
Stock-Based Compensation	Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company’s stock based compensation consisted of the following during the three months ended March 31, 2015 and 2014, respectively:
		March 31,		March 31,
		2015		2014
	Common stock issued for services	$	-	$	97,000
	Warrants issued for services		209,957		49,751
	Warrants issued for services, related parties		825,778		-
	Total stock based compensation	$	1,035,735	$	146,751
Revenue Recognition	Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales have not yet commenced.
Advertising and Promotion	All costs associated with advertising and promoting products are expensed as incurred. These expenses were $11,517 and $35,317 for the three months ended March 31, 2015 and 2014, respectively.
Income Taxes	Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.
Uncertain Tax Positions	In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.
	Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities.
	The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.
Recent Accounting Pronouncements	In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, Interest–Imputation of Interest (Subtopic 835-30) (“ASU 2015-03”), which changes the presentation of debt issuance costs in financial statements. ASU 2015-03 requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. It is effective for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The new guidance will be applied retrospectively to each prior period presented. The Company is currently in the process of evaluating the impact of adoption of ASU 2015-03 on its balance sheets.
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period, and early application is not permitted. ASU 2014-09 allows for either full retrospective or modified retrospective adoption. We do not expect the adoption of the new provisions to have a material impact on our financial condition or results of operations.
	No other new accounting pronouncements, issued or effective during the first quarter of 2015, have had or are expected to have a significant impact on the Company’s financial statements.

Nature_of_Business_and_Signifi2

Nature of Business and Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Nature Of Business And Significant Accounting Policies Tables
Stock-Based Compensation		March 31,		March 31,
		2015		2014
	Common stock issued for services	$	-	$	97,000
	Warrants issued for services		209,957		49,751
	Warrants issued for services, related parties		825,778		-
	Total stock based compensation	$	1,035,735	$	146,751

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Of Financial Instruments Tables
Fair Value of Financial Instruments	The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of March 31, 2015 and December 31, 2014, respectively:
		Fair Value Measurements at
		31-Mar-15
		Level 1		Level 2			Level 3
	Assets
	Cash	$	95,930	$	-		$	-
	Total assets		95,930		-			-
	Liabilities
	Convertible note payable, net of discounts		-		118,453			-
	Total liabilities		-		118,453			-
		$	95,930	$	(118,453	)	$	-
		Fair Value Measurements at
		31-Dec-14
		Level 1		Level 2			Level 3
	Assets
	Cash	$	102,599	$	-		$	-
	Total assets		102,599		-			-
	Liabilities
	Convertible note payable, net of discounts		-		14,879			-
	Total liabilities		-		14,879			-
		$	102,599	$	(14,879	)	$	-

Convertible_Note_Payable_Table

Convertible Note Payable (Tables)	3 Months Ended
	Mar. 31, 2015
Convertible Note Payable Tables
Summary of convertible note payable	Convertible notes payable consist of the following at March 31, 2015 and December 31, 2014, respectively:
		31-Mar-15		31-Dec-14
	On February 24, 2015, we entered into a Securities Purchase Agreement with Adar Bays, LLC (“Adar Bays”), pursuant to which we sold to Adar Bays an 8% Convertible Promissory Note in the original principal amount of $44,100.00 (the “First Adar Note”). The Note has a maturity date of February 24, 2016, and is convertible after 180 days into our common stock at the higher of (i) $0.001 cents per share or (ii) 70% of the average of the two (2) lowest closing prices of our common stock for the fifteen (15) trading days prior to receipt of a conversion notice from Adar Bays. The shares of common stock issuable upon conversion of the Note will be restricted securities as defined in Rule 144 promulgated under the Securities Act of 1933. The Note can be prepaid by us at a premium as follows:	$	44,100	$	-
	(a) between 1 and 30 days after issuance – 115% of the principal amount;
	(b) between 31 and 60 days after issuance – 121% of the principal amount;
	(c) between 61 and 90 days after issuance – 127% of the principal amount;
	(d) between 91 and 120 days after issuance – 133% of the principal amount;
	(e) between 121 and 150 days after issuance – 139% of the principal amount; and
	(f) between 151 and 180 days after issuance – 140% of the principal amount.
	There is no right to pre-payment after 180 days. The purchase and sale of the Note closed on March 2, 2015, the date that the purchase price was delivered to us.
	On January 30, 2015, we entered into a Securities Purchase Agreement with LG Capital Funding, LLC (“LG Capital”), pursuant to which we sold to LG Capital a 8% Convertible Promissory Note in the original principal amount of $82,687.00 (the “ Second LG Note”). The Note has a maturity date of January 29, 2016, and is convertible after 180 days into our common stock at the higher of (i) $0.001 cents per share or (ii) 70% of the average of the two (2) lowest closing bid prices of our common stock for the fifteen (15) trading days prior to receipt of a conversion notice from LG Capital. The shares of common stock issuable upon conversion of the Note will be restricted securities as defined in Rule 144 promulgated under the Securities Act of 1933. The Note can be prepaid by us at a premium as follows:		82,687		-
	(a) between 1 and 30 days after issuance – 115% of the principal amount;
	(b) between 31 and 60 days after issuance – 121% of the principal amount;
	(c) between 61 and 90 days after issuance – 126% of the principal amount;
	(d) between 91 and 120 days after issuance – 132% of the principal amount;
	(e) between 121 and 150 days after issuance – 138% of the principal amount; and
	(f) between 151 and 180 days after issuance – 140% of the principal amount.
	There is no right to pre-payment after 180 days. The purchase and sale of the Note closed on January 30, 2015, the date that the purchase price was delivered to us.
	On November 25, 2014, the Company received an unsecured loan from Typenex Co-Investment, LLC (“First Typenex Note”) in the amount of $86,500, bearing interest at 10%, maturing on August 25, 2015, in exchange for net proceeds of $75,000 after the deduction of $4,000 of loan origination costs and an original issue discount (“OID”) of $7,500. The Company also issued Typenex warrants to purchase 351,455 shares of common stock at a strike price of $0.18 per share over a five year term from the date of investment. The principal and interest is convertible into shares of common stock at the discretion of the note holder at the lesser of (i) $0.18 per share, or (ii) 70% (the “Conversion Factor”) multiplied by the Market Price (as defined in the Note). If the Market Price of our common stock falls below $0.10 per share after the issuance of the Note, the Conversion Factor will automatically be reduced by 5% for all conversions completed while the Market Price is below $0.10 per share. Notwithstanding the foregoing, so long as no Event of Default has occurred, the Conversion Price shall be not less than $0.0001 (the “Conversion Floor”). For the avoidance of doubt, upon the occurrence of an Event of Default, the Conversion Floor shall not apply to any future Conversions and shall be of no further force or effect. The note can be prepaid upon notice to Typenex any time prior to the first conversion at a premium of 120% of the then outstanding balance of the Note. The note carries a default interest rate of 22% per annum.		86,500		86,500
	Total convertible notes payable		213,287		86,500
	Less unamortized debt discounts:
	Discount on beneficial conversion feature		65,166		32,137
	Original issue discount		9,216		6,511
	Discount on warrants		20,452		32,973
	Convertible notes payable		118,453		14,879
	Less: current portion		118,453		14,879
	Convertible notes payable, less current portion	$	-	$	-
Interest expense related to the convertible debts	The Company recognized interest expense for the three months ended March 31, 2015 and 2014, respectively, as follows:
		March 31,		March 31,
		2015		2014
	Interest on convertible notes	$	3,476	$	-
	Interest on related party loans		-		29,455
	Amortization of loan origination costs		2,138		-
	Amortization of beneficial conversion feature		19,534		-
	Amortization of OID		3,332		-
	Amortization of warrants		12,521		-
	Total interest expense	$	41,001	$	29,455

Income_Taxes_Tables

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2015
Income Taxes Tables
Deferred tax asset	The components of the Company’s deferred tax asset are as follows:
		March 31,			December 31,
		2015			2014
	Deferred tax assets:
	Net operating loss carry forwards	$	755,000		$	675,610
	Net deferred tax assets before valuation allowance	$	755,000		$	675,610
	Less: Valuation allowance		(755,000	)		(675,610	)
	Net deferred tax assets	$	-		$	-
Reconciliation between the amounts of income tax	A reconciliation between the amounts of income tax benefit determined by applying the applicable U.S. and state statutory income tax rate to pre-tax loss is as follows:
		March 31,			December 31,
		2015			2014
	Federal and state statutory rate		35%			35%
	Change in valuation allowance on deferred tax assets		-35%			-35%

Nature_of_Business_and_Signifi3

Nature of Business and Significant Accounting Policies (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Nature Of Business And Significant Accounting Policies Details
Common stock issued for services		$97,000
Warrants issued for services	209,957	49,751
Warrants issued for services, related parties	825,778
Stock based compensation	$1,035,735	$146,751

Nature_of_Business_and_Signifi4

Nature of Business and Significant Accounting Policies (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Nature Of Business And Significant Accounting Policies Details Narrative
Advertising and promotion expenses	$11,517	$35,317

Going_Concern_Details_Narrativ

Going Concern (Details Narrative) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Going Concern Details Narrative
Accumulated deficit	($9,463,061)	($8,195,626)
Working capital deficit	($251,598)

Related_Parties_Details_Narrat

Related Parties (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Related Parties Details Narrative
Amount owed to Chairman of the Board of Directors	$12,729		$11,069
Amount owed to CEO	431		465
Amount owed to Boards of Directores	13,765		13,765
Stock based compensation, related parties	$825,778

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Cash	$95,930	$102,599	$113,591
Convertible note payable, net of discounts	118,453	14,879
Fair Value, Measurements, Recurring [Member] | Level 1 [Member]
Cash	95,930	102,599
Total assets	95,930	102,599
Convertible note payable, net of discounts
Total liabilities
Net assets and liabilities	95,930	102,599
Fair Value, Measurements, Recurring [Member] | Level 2 [Member]
Cash
Total assets
Convertible note payable, net of discounts	118,453	14,879
Total liabilities	118,453	14,879
Net assets and liabilities	-118,453	-14,879
Fair Value, Measurements, Recurring [Member] | Level 3 [Member]
Cash
Total assets
Convertible note payable, net of discounts
Total liabilities
Net assets and liabilities

Convertible_Note_Payable_Detai

Convertible Note Payable (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Total convertible note payable	$213,287	$86,500
Less unamortized debt discounts:
Discount on beneficial conversion feature	65,166	32,137
Original issue discount	9,216	6,511
Discount on warrants	20,452	32,973
Convertible note payable	118,453	14,879
Less: current portion	118,453	14,879
Convertible note payable, less current portion
On February 24, 2015 [Member]
Total convertible note payable	44,100
On January 30, 2015 [Member]
Total convertible note payable	82,687
On November 25, 2014 Unsecured loan [Member]
Total convertible note payable	$86,500	$86,500

Convertible_Note_Payable_Detai1

Convertible Note Payable (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Convertible Note Payable Details 1
Interest on convertible notes	$3,476
Interest on related party loans		29,455
Amortization of loan origination costs	2,138
Amortization of beneficial conversion feature	19,534
Amortization of OID	3,332
Amortization of warrants	12,521
Total interest expense	$41,001	$29,455

Convertible_Note_Payable_Detai2

Convertible Note Payable (Details Narrative) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Debt amortization expense	$19,534	$0
Beneficial conversion feature of convertible note	52,563		37,019
Typenex Co-Investment, LLC Convertible Note [Member]
Debt amortization expense	12,204	0
LG Capital Funding, LLC Convertible Note [Member]
Debt amortization expense	5,372	0
Adar Bays, LLC Convertible Note [Member]
Debt amortization expense	$1,958	$0

Changes_in_Stockholders_Equity1

Changes in Stockholders Equity (Deficit) (Details Narrative) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Changes In Stockholders Equity Deficit Details Narrative
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized shares	10,000,000	10,000,000
Series A Convertible Preferred Stock designated	2,000,000
Common stock, par value	$0.00	$0.00
Common stock, authorized shares	300,000,000	300,000,000

Common_Stock_Warrants_Details_

Common Stock Warrants (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Professional fee	$1,086,332	$227,292
Stock based compensation expense	209,957	146,751
Stock based compensation, related parties	825,778
Volatility rate	204.00%
Call option price	$0.12
Common Stock Warrants [Member]
Professional fee	1,035,735	49,751
Stock based compensation expense	$58,301

Income_Taxes_Details

Income Taxes (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Net operating loss carry forwards	$755,000	$675,610
Net deferred tax assets before valuation allowance	755,000	675,610
Less: Valuation allowance	-755,000	-675,610
Net deferred tax assets

Income_Taxes_Details_1

Income Taxes (Details 1)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Income Taxes Details 1
Federal and state statutory rate	35.00%	35.00%
Change in valuation allowance on deferred tax assets	-35.00%	-35.00%

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Income Taxes Details Narrative
Federal net operating losses	$2,157,014	$1,930,314
Federal net operating losses expire	2031